• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Latest

Hiding in the Numbers: How the Medical and Healthcare Industry Betrayed the World

Like 0

By Brian Chu, Tuesday, 26 March 2024

You often find the corruption and deceit in the numbers!

In today’s Fat Tail Daily, There are many ways that the authorities can deceive us. They usually hide it in the numbers. In today’s update, I’ll share with you some startling findings I made when delving into Pfizer’s mRNA vaccine trials data. I’ll show you how they played the numbers game. While this is all in the past, it’s important that you protect yourself and those closest to you as public trust is plummeting to all-time lows.

Last week I wrote about the Riverina State, a concept that seeks to improve the representation of rural New South Wales and Victorian voters.

That wasn’t the only major takeaway from the conference.

Another was building a connection with the Australian Medical Professionals Society (AMPS). This society comprises doctors, nurses and other healthcare professionals that the mainstream medical community sidelined in the last four years.

They’re currently delving into the validity of lockdowns and vaccine mandates. The Society has delivered many publications, some of which I’ve studied.

And…

I’ve started participating in analysing the data. In particular, I’m going down the trail of the ‘numbers game’ that the medical and healthcare establishment played to set the narrative and put in place certain mandates.

While the establishment owns the prevailing narrative, I believe that they’ve overplayed their hand. Not only that, their deceit is catching up with them.

I’ll talk about that today.

Most of you know I’ve penned articles in the last three years expressing my doubts and outrage at how the medical and healthcare industry betrayed the people’s trust.

My earlier articles discussed the government overreach and the excesses it committed during the global virus outbreak.

I expressed my doubts about the accuracy of the instruments, the logic behind the emergency measures and whether ulterior motives exist, such as using fear to control the population.

As time passed, I shared with you some findings from my analyses (or by others) that suggests the possibility of malfeasance by the authorities and the pharmaceutical companies.

This included the admission by a Pfizer executive to the European Union Parliament in October 2022 that it had rushed the trials and release of its mRNA experimental drug. Since the global rollout, it has received mixed response especially as adverse side effects mount.

Another is the ‘Twitter Files’ that revealed a coordinated campaign to censor dissenting opinions and suppress studies that went against their narrative. It involved the World Health Organization, government agencies, pharmaceutical companies, mainstream media outlets, social media platforms and the medical research community.

I’ve also shown you the journal articles that hid the truth in plain sight. The results in these articles either don’t match the conclusions or the authors omit points that may counter their message.

Tide turned, backlash building

The prevailing narrative is that the mRNA drugs were 100% safe and effective, masks stopped the spread, and claims of hydroxychloroquine and ivermectin being effective alternative treatments are false.

However, time has passed and this narrative is crumbling fast.

With every big lie, there comes a time of reckoning. You often will see signs of the backlash well before the crunch.

It may be public support turning into doubt. Or the authority walks back quietly on something that they once staunchly defended.

To show you what I mean, let’s look at the price of Pfizer [NYSE:PFE], the leading manufacturer of the mRNA vaccine, over the last few years:

Fat Tail Investment Research

Source: Refinitiv Eikon

[Click to open in a new window]

It has been in freefall since mid-2022 as the global uptake of their drugs fell.

I believe that it’ll get far worse as the company faces the music over its malpractice. But unlike the past, the government won’t give it immunity against damages that its product caused. I’ll cover that in a short while.

Another is the Food & Drug Administration (FDA). Last Friday, it lost its case in the US Fifth Circuit Court of Appeals against three doctors suing over its public messages to suppress ivermectin as an effective treatment against the Wuhan virus and its myriad ‘variants’.

Remember this?

Fat Tail Investment Research

Source: X (@US_FDA)

[Click to open in a new window]

Some of my relatives, friends and I (all humans and not livestock, mind you) used ivermectin when we fell sick back then. None of us experienced any harm, most of us experienced a quick recovery.

This ad along with other public messages will soon disappear…but not to be forgotten.

This leads me to the next point.

The Emergency Use Authorisation…the
devil’s in the details

So, why the big deal over the mRNA drug, the medical industry and the alternative treatments?

A battle is looming in the not-so-distant future. It’ll be between the growing number of people harmed by the drug against the authorities and manufacturers who forced it on them while hiding crucial facts about its risks.

The conditions stated in the Emergency Use Authorisation (EUA) will eventually determine who wins.

For those unfamiliar, in November 2020, the US government granted the manufacturers a fast-track process to develop and roll out these drugs under the EUA.

You can read the details of the conditions in the FDA website.

Normally such drugs would need to undergo years of testing and review before its release to the market.

But governments wanted to allay people’s concerns during this outbreak. With directives from the WHO, many were made to believe that vaccines would do the job.

The EUA would facilitate a fast release of these drugs into the market, provided that no alternative treatments are available and the drug manufacturers passed the criteria set by the FDA.

On the first point, you can see the peculiar case of how the FDA weighed in on ivermectin, along with hydroxychloroquine and various vitamins.

For several years this message stuck, but now it has faced a humiliating defeat and retraction.

The second point is more concerning. In early-2022, the FDA had to release to the public the data submitted by the vaccine manufacturers.

The spotlight is now shining on Pfizer, although other manufacturers aren’t off the hook.

Omitting crucial data to tilt the game

A recently published paper identified several data inconsistencies by studies testing the efficacy of the mRNA drugs. You can find the paper here.

Key issues included shortening the trial period, miscategorising observations, and evidence of cherry-picking data to deliver a desired outcome.

Earlier this month, Michels et al published a paper in the International Journal of Vaccine Theory, Practice, and Research that highlighted the inconsistencies with the Pfizer trial data could’ve changed the outcome of the FDA approval to release its product to market.

I conducted some statistical tests on the data found in the paper to confirm the findings.

Firstly, the data sent to Pfizer claimed that of the 6 participants who died in the trials leading up to the submission date for EUA approval, 2 received the mRNA drug and 4 received the placebo.

However, Pfizer subsequently released an interim report in March 2021 that showed 11 participants died during that period. 6 received the drug and 5 received the placebo.

The results showed the drug didn’t deliver a significant effect if you consider the 11 participants who died.

Moreover, by withholding 5 observations, Pfizer tipped the result in favour of its claim that its drug was effective.

As I write this article, the analysis continues. The authors of this paper will no doubt release more findings as time passes.

Now, I can’t conclude from my analysis and the findings thus far that this proves Pfizer intentionally put profits ahead of helping people.

But it all becomes more suspicious when you consider the concerted effort to censor dissenting opinions and threats to deregister medical practitioners for not standing in line.

I’ll leave you to be the judge.

Take steps to protect yourself…think gold!

Before I end this article, I want to leave you with this thought.

Public trust has plummeted across the board. Many things we used to take for granted we can’t anymore.

That’s why you should protect yourself and those closest to you.

For me, I take my refuge in gold. It’s something that the authorities seek to disparage. That’s why I like it even more.

Over the past decade, I’ve studied the gold market in great depth and that’s helped me deliver solid returns.

You can find out more about my work in my precious metals investment newsletter, The Australian Gold Report.

You’ll find unique metrics and perspectives in this service that don’t exist anywhere else. That’s because I developed them through years of experience and analysis.

With gold breaking into new all-time highs, this is a great time to jump on board.

So, consider signing up now and make a difference to your future!

God bless,

Brian Chu Signature

Brian Chu,
Editor, Gold Stock Pro and The Australian Gold Report

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Brian Chu

Brian Chu is one of Australia’s foremost independent authorities on gold and gold stocks, with a unique strategy for valuing big producers and highly speculative explorers. He established a private family fund that only invests in ASX-listed gold mining companies, possibly the only such fund in Australia, putting his strategy and research skills to the test under public scrutiny. He currently writes two gold-focused investment advisories.

In his Australian Gold Report, Brian shows you a strategy for building long-term wealth in physical gold, along with a select portfolio of hand-picked stocks, mainly producers with proven revenue streams, chosen for their balance of risk and reward.

In his more specialised Gold Stock Pro service, Brian helps readers trade some of the most exciting, speculative gold mining plays on the ASX. He uses his proprietary system — based on the famous Lassonde Curve model, which tracks the life cycle of mining stocks. His aim is to help you get ready to trade the next phase of gold and silver’s anticipated longer-term bull market for opportunities to benefit.

Brian’s Premium Subscriptions

Publication logo
The Australian Gold Report
Publication logo
Gold Stock Pro

Latest Articles

  • Google Search Isn’t Dead, It Just Smells Funny
    By Charlie Ormond

    The question isn't whether this disruption will happen, but whether you're positioned to profit from it.

  • Trump sparks uranium rally
    By Callum Newman

    Tune in today to watch the latest Closing Bell podcast with Murray Dawes. We discuss the outlook for US stocks, uranium, RBA “bulltish”…plus discuss a few stocks. Tune in now!

  • Markets on Edge? Who cares, this Explorer just delivered a 1,600m Hit
    By James Cooper

    James Cooper outlines the potential opportunities among explorers making major drill hits, but aren’t capturing attention from investors, yet.

Primary Sidebar

Latest Articles

  • Google Search Isn’t Dead, It Just Smells Funny
  • Trump sparks uranium rally
  • Markets on Edge? Who cares, this Explorer just delivered a 1,600m Hit
  • Just “ChatGPT It”, Stupid
  • The blunder that cost Australia $28 billion

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988